GlassScriptPhysician profile
Aggie J Sutherland
NPI 1053905331
$1,350.69
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $478 · 2023: $732 · 2024: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $232.36 | 2022-2023 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.87 | 2023 | Relistor |
| Abbvie INC. | $157.51 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $151.27 | 2022 | |
| Vertos Medical, INC. | $139.80 | 2024 | Mild Device Kit |
| Electronic Waveform Lab, INC. | $118.19 | 2022-2023 | |
| Averitas Pharma INC. | $58.07 | 2023 | Qutenza |
| Collegium Pharmaceutical, INC. | $54.32 | 2022-2023 | Xtampza |
| Pfizer INC. | $52.73 | 2023 | |
| Scilex Pharmaceuticals INC. | $43.59 | 2023 | Ztlido |
| Hikma Pharmaceuticals USA | $39.40 | 2022 | |
| Ibsa Pharma INC. | $37.04 | 2023 | Tirosint, Licart |
| Lilly USA, LLC | $25.22 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $24.99 | 2023 | Dysport |
| Novo Nordisk INC | $16.52 | 2023 | Wegovy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $16.17 | 2023 | Horizant |
| Fidia Pharma USA INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aggie Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.